CD4 and cancer: Clinical characteristics, coexisting mutations, and outcomes to EGFR‐TKIs and immune checkpoint blockade were reviewed for NSCLC patients with exon 20 mutations of EGFR or HER2. Data obtained included the molecular spectrum (extended genotyping for mutations in 324 cancer‐related genes), as well as tumor mutational burden (TMB), PD‐L1 protein expression, and the abundance of CD4+ and CD8+ tumor‐infiltrating lymphocytes (TILs).